A Study Testing the Safety and Possible Benefits of an Ear Injection of a New Compound, Paliroden, in People With Type 2 Diabetes Who Have Difficulty Understanding Speech in Noisy Situations
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: CIL001 (Paliroden), Placebo.
- Who it may be relevant to
- Registry conditions: Cochlear Synaptopathy. Basic parameters: 45 years — 75 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Center list to be confirmed — check the primary protocol.
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
A Randomized, Double-blind, Placebo-controlled, Ascending Volume Phase 1B/2A Clinical Trial to Investigate the Safety and Efficacy of a Single Transtympanic Injection of CIL001 (Paliroden) for the Treatment of Cochlear Synaptopathy in Participants With type2 Diabetes
Overview
Like retinopathy, neuropathy and nephropathy, sensorineural hearing loss is a common and underserved complication of uncontrolled diabetes. Neuroinflammation in diabetes can cause auditory nerve damage (cochlear synaptopathy) which first translates into speech-in-noise intelligibility deficit. CIL001 is a neurotrophic small molecule that aims to repair auditory nerve when applied locally by transtympanic injection. Transtympanic injection of paliroden is anticipated to improve the symptoms of cochlear synaptopathy. Furthermore, by addressing auditory or vestibular dysfunction early and effectively, this approach may contribute to limiting or delaying, over the long term, the onset of secondary neurological disorders, such as dementia.
Interventions
- Drug CIL001 (Paliroden)
Single unilateral transtympanic administration - Drug Placebo
Placebo
Primary outcome measures
- Frequencies of Treatment-Related Adverse Events with a particular focus on ear and auditory symptomatology [Time frame: Over 6 month (168 days) post-injection]
Secondary outcome measures (5)
- Determine the concentration in plasma of paliroden with Area under the plasma concentration versus time curve (AUC) [Time frame: From the day of injection to 28 days]
- Determine the concentration in plasma of paliroden with Peak Plasma Concentration (Cmax) [Time frame: From the day of injection to 28 days]
- Determine the concentration in plasma of paliroden with Time to maximum concentration (Tmax) [Time frame: From the day of injection to 28 days]
- Change in speech in noise intelligibility base on the SRT50 result From the Matrix test (SRT50 = Signal-to-noise ratio required to correctly understand 50% of presented speech) [Time frame: At Day 84 from baseline]
- Change in ABR Wave I amplitude (µV) measured by electrocochleography [Time frame: Day 28, Day 84, Day 168]
Eligibility criteria
Inclusion criteria
- Signed and dated informed consent form
- Aged between 45 and 75 years old (inclusive) at the time of screening
- Established type 2 diabetes as determined by 7% ≤ hemoglobin A1c (HbA1c) ≤ 9% and diabetes duration of at least 5 years
- Be considered as reliable and capable of adhering to the protocol, according to the judgment of the Investigator
- Participants must be native speakers of the official language(s) of the country in which the study assessments are conducted.
- Women of childbearing potential (WOCBP) must have a negative serum pregnancy test upon entry into this study. In addition, they must agree to use highly effective contraception methods, as defined by regulatory guidance (e.g., combined hormonal contraception, intrauterine device, or surgical sterilization), from the screening visit, for the duration of study treatment and for 30 days after dosing.
The following audiology assessments, if not performed on the same day as the review of the previous criteria (e.g., when the participant's first visit does not take place at the ENT site), may be scheduled on different days within a maximum interval of 14 days after the first screening visit and must be completed at least 21 days before the baseline visit.
- Normal hearing as defined by PTAv (0.5-1-2kHz-4Khz) <25dB in both ears.
- Up to mild hearing loss in the high-frequency range (PTAvHF (4-6-8kHz) <40dB) in both ears.
- Speech-in-noise deficit (at least 3dB SNR loss in comparison to normative value of the Matrix test) in both ears.
Exclusion criteria
- MoCA score < 26
- Known otologic pathology (e.g., History of autoimmune hearing loss, radiation-induced hearing loss, fluctuating hearing, endolymphatic hydrops, or Menière's disease in either ear)
- Presence of middle ear pathology (e.g., otitis media, tympanic membrane perforation, etc.)
- History of platinum-based chemotherapy
- Previous or concurrent malignancies that require treatment and are not clinically stable
- Current evidence or history of retrocochlear pathology (e.g., acoustic neuroma)
- History of otologic surgery (apart from tympanostomy tube insertion if more than one year prior to inclusion visit)
- Abnormal otoscopy as defined by less than 90% of the tympanic membrane visible (e.g., cerumen ear plug, ear drum perforation). In case of cerumen plugs not affecting the hearing results, a removal must be scheduled before V1 (baseline/inclusion).
- Hearing aids and cochlear implants.
- History of cancer treated by platinum-based chemotherapy.
- Lactation or known pregnancy or positive pregnancy test at both screening and baseline for women of childbearing potential, or planning to become pregnant during the study
- Liver Enzyme Lab Outcomes:
- Bilirubin > 2 times the upper limit of normal (ULN)
- Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) (AST/ALT) >5 times ULN.
- Gamma glutamyltransferase (GGT) > 5 times ULN
- Maternally Inherited Diabetes
- Congenital hearing loss
- Untreated hypothyroidism
- Adult individual under legal protection as defined by applicable regulations (e.g., persons deprived of liberty, hospitalized without consent, unable to provide informed consent, or placed under legal guardianship or curatorship)
- Concurrent participation in another clinical study or participation in another trial involving experimental drug within 30 days or five half-lives of the experimental drug (whichever was longer) prior to screening visit (V0).
- Diagnosed anxiety disorders, psychosis, depression, schizophrenia, attempted suicide, or other significant psychiatric conditions that could impact their ability to cooperate and comply with the study protocol
- Major surgery that may impact the study conduct or outcomes within eight weeks before screening or scheduled/planned surgery within the time frame of the study
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Quadruple blind
- Primary purpose
- Treatment
Study locations
Center list to be confirmed — check the primary protocol.
Identifiers
NCT: NCT07472907 · RESPLAND · 2025-524383-37-00